Validación del índice ReXSPA (Reductive X-ray Score for Psoriatic Arthritis) en pacientes con Artritis Psoriásica de la cohorte RAPSODIA

Carolina  Isnardi; Fernando  Dal Para; Eduardo  Scheines; Marina  Fornaro; Osvaldo  Cerda; Gustavo  Citera; Emilce  Schneeberger

doi:10.47196/rar.v31i2.402

Carolina Isnardi Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
Fernando Dal Para Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
Eduardo Scheines Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
Marina Fornaro Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
Osvaldo Cerda Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
Gustavo Citera Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
Emilce Schneeberger Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v31i2.402

Palabras clave: Artritis Psoriásica, daño estructural, ReXSPA

Resumen

Existen diversos índices capaces de valorar el daño radiográfico en pacientes con artritis psoriásica (APs), sin embargo, la mayoría fueron creados para su uso en Artritis Reumatoidea y luego modificados para APs, por lo tanto no valoran lesiones características como la osteoproliferación. El objetivo de este estudio fue validar el Reductive X-Ray Score for Psoriatic Arthritis (ReXSPA), el cual fue recientemente desarrollado para su uso en cohortes observacionales. Material y métodos: estudio de corte transversal, en el cual se incluyeron pacientes ≥18 años de edad, en forma consecutiva, con diagnóstico de APs según criterios CASPAR. A todos los pacientes se les realizaron radiografías de manos y pies en proyección anteroposterior. Dos lectores ciegos para las características clínicas de los pacientes y previamente entrenados, analizaron las mismas por medio de los índices Sharp van der Heijde modificado para APs (SvdHmAPs) y ReXSPA. Se midió el tiempo empleado para la lectura de los índices radiográficos y para el cálculo de los mismos.

Citas

I. Maldonado Coco J, Citera G. Reumatología.1era edición. Capítulo 33. Pág. 462-77.

II. Orbai A, de Wit M, Mease P, Shea J, Gossec L, Leung Y, et al. Interna-tional patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 2017;76(4):673-80.

III. Gladman D, Farewell V, Wong K, Husted J. Mortality studies in pso-riatic arthritis. Arthritis Rheum 1998;41(6):1103-10.

IV. Sudol-Szopinska I, Matuszewska G, Kwiatkowska B, Pracon G. Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features. J Ultrason 2016;16(64):65-77.

V. van der Heijde D, Sharp J, Wassenberg S, Gladman D. Psoriatic ar-thritis imaging: a review of scoring methods. Ann Rheum Dis 2005; 64(Suppl II):ii61-ii64.

VI. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665-73.

VII. Sharp J, Bluhm G, Brook A, Brower A, Corbett M, Decker J, et al. Re-producibility of multiple-observer scoring of radiologic abnormali-ties in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 1985;28(1):6-24.

VIII. van der Heijde D. How to read radiographs according to the Sharp/ van der Heijde method. J Rheumatol 2000;27(1):261-3.

IX. Rahman P, Gladman D, Cook R, Zhou Y, Young G, Salonen D. Ra-diological assessment in psoriatic arthritis. Br J Rheumatol 1998;37(7):760-5.

X. Wassenberg S, Fischer-Kahle V, Herborn G, Rau R. A method to score radiographic change in psoriatic arthritis. Z Rheumatol 2001;60(3):156-66.

XI. Wassenberg S. Radiographic scoring methods in psoriatic arthritis. Clin Exp Rheumatol 2015:33(Suppl. 93):S55-9.

XII. Salaffi F, Carotti M, Beci G, Di Carlo M, Giovagnoni A. Radiographic scoring methods in rheumatoid arthritis and psoriatic arthritis. Radiol Med 2019;124(11):1071-86.

XIII. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34(5):1167-70.

XIV. Antoni C, Krueger G, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64(8):1150-57.

XV. Kavanaugh A, McInnes I, Mease P, Krueger G, Gladman D, van der Heijde D, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689-1694.

XVI. Tillett W, Jadon D, Shaddick G, Robinson G, Sengupta R, Koren-dowych E, et al. Feasibility, reliability and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthi-tis. Arthritis Care Res 2014;66(2):311-7.

XVII. Tillett W, Shaddick G, Jadon D, Robinson G, Korendowych E, McHuch N. Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study. J Rheumatol 2016;43(2);367-70.

XVIII. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665-73.

XIX. JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1):55-78.

XX. Healy P, Helliwell P. Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 2007;34(6):1302-6.

XXI. Deandrade JR, Casagrande PA. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965;8:302-34.

XXII. Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, et al. Endorsement of the 66/68 Joint Count for the Measu-rement of Musculoskeletal Disease Activity: OMERACT 2018 Pso-riatic Arthritis Workshop Report. J Rheumatol 2019;46(8):996-1005.

XXIII. Healy P, Helliwell P. Measuring dactylitis in clinical trials: which is the best instrument to use? J Rheumatol 2007;34(6):1302-6.

XXIV. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van der Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62(2):127-32.

XXV. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157(4):238-44

XXVI. Citera G, Arriola M, Maldonado-Cocco J, Rosemffet M, Sánchez M, Goñi M, et al. Validation and crosscultural adaptation of an Argen-tine spanish version of the health assessment questionnaire disa-bility index. J Clin Rheumatol 2004;10(3):110-5.

XXVII. McKenna S, Doward L, Whalley D, Tennant A, Emery P, Veale D. De-velopment of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63(2):162-9.

XXVIII. Finlay A, Khan G. Dermatology Life Quality Index (DLQI)-a sim-ple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-6.

XXIX. Prevoo MLL, van´t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a pros-pective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38(1):44-8.

XXX. Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen J. Development of a disease activity index for the assessment of re-active arthritis (DAREA). Rheumatology (Oxford) 2000;39(2):148-55.

XXXI. Coronel Ale AL, Schneeberger EE, Cerda OL, Zaffarana C, Fornaro MN, Landi M, et al. Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available. Arthritis Rheumatol 2017;69(suppl 10).

XXXII. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates L, Veale J. De-velopment of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70(2):272-7.

XXXIII. Coates L, Fransen J, Helliwell P. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69(1):48-53.

XXXIV. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clini-cal and radiological damage in psoriatic arthritis. Ann Rheum Dis 2006;65(4):478-81.

XXXV. Geijer M, Lindqvist U, Husmark T, Alenius GM, Larsson PT, Teleman A, et al. The Swedish Early Psoriatic Arthritis Registry 5-year Fo-llowup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis. J Rheumatol 2015;42(11):2110-7.

XXXVI. Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Pu-tte LB, van Riel PL. Assessment of outcome in ankylosing spond-ylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64(1):127-9.

XXXVII. . Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, et al. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol 2016;34(4 Suppl 98):69-76.

XXXVIII. van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther 2020;22(1):18

XXXIX. Antony A, Allard A, Shaddick G, Jadon D, Cavill C, Korendowych E, et al. Ability of the reductive x-ray score for psoriatic arthritis (REXSPA) to detect change in an observational cohort of patients with PsA. Ann Rheum Dis 2018;77(Supl):1578-9.

XL. Salaffi F, Carotti M, Di Donato E, Di Carlo M, Luchetti MM, Ceccarelli L, et al. Preliminary validation of the Simplified Psoriatic Arthritis Radiographic Score (SPARS). Skeletal Radiol 2019;48(7):1033‐41.

XLI. Marchesoni A, Caporali R, Lubrano E. Clinical implications of peri-pheral new bone formation in psoriatic arthritis: a literature-based review. Clin Exp Rheumatol 2019;37(2):310-7.

XLII. Kampylafka E, d’Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A lockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther 2018;20(1):153.

XLIII. Poggenborg RP, Bird P, Boonen A, Wiell C, Pedersen SJ, Sørensen IJ, et al. Pattern of bone erosion and bone proliferation in psoriatic arthritis hands: a high-resolution computed tomography and ra-diography follow-up study during adalimumab therapy. Scand J Rheumatol 2014;43(3):202-8.

XLIV. US Food and Drug Administration. https://www.fda.gov/consu-mers/consumer-updates/reducing-radiation-medical-x-rays.

XLV. Burghardt AJ, Buie HR, Laib A, Majumdar S, Boyd SK. Reproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT. Bone 2010;47(3):519-28.

XLVI. Kallman DA, Wigley FM, Scott WW Jr, Hochberg MC, Tobin JD. New radiographic grading scales for osteoarthritis of the hand. Reliabi-lity for determining prevalence and progression. Arthritis Rheum 1989;32(12):1584-91.

XLVII. . Tan AL, Grainger AJ, Tanner SF, Emery P, McGonagle D. A high-reso-lution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum 2006;54(4):1328-33.

XLVIII. Finzel S, Sahinbegovic E, Kocijan R, Engelke K, Englbrecht M, Schett G. Inflammatory bone spur formation in psoriatic arthritis is di-fferent from bone spur formation in hand osteoarthritis. Arthritis Rheumatol 2014;66(11):2968-75.